MDGL — Madrigal Pharmaceuticals, Inc.

Float: 14.9M shares. Latest SEC filing: S-8 on Jun 17, 2026. MDGL closed at $431.15 (+0.18%) on Nov 2, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for MDGL in the TickerWise workspace.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 528
• Website: https://www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Latest SEC filings for MDGL

• 2026-06-17S-8
• 2026-05-15SCHEDULE 13G/A
• 2026-05-068-K
• 2026-05-0610-Q
• 2026-04-288-K
• 2026-04-28ARS
• 2026-03-27SCHEDULE 13G/A
• 2026-02-1910-K
• 2026-02-198-K
• 2026-01-308-K

Latest MDGL news

• 2026-11-02Madrigal Pharmaceuticals Q3 2026 Earnings Preview Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.